Clinical trials
Steatohepatitis clinical trials
Below are recruiting steatohepatitis clinical trials, each written for real people, not researchers. We’re tracking 95 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05945537RecruitingPhase 1
Testing INI-822 in healthy people and those with MASH
This study tests a new oral medication (INI-822) to see if it’s safe and how the body handles it in healthy volunteers and in people with MASH. MASH is a type of fatty liver disease with inflammation and possible scarring. If you have MASH, the study also checks if the drug can improve markers of liver health. You will need to come to the study site for visits and follow strict guidelines about birth control, alcohol, and other medicines.
Camperdown, New South WalesAges 18–70 - NCT05720663Recruiting
Predicting liver outcomes in fatty liver cirrhosis
This study looks at how to predict future outcomes in adults who have fatty-liver disease (NAFLD) that has progressed to cirrhosis. It may help doctors better estimate risk and plan care, using information from liver tests and scans.
Rochester, MinnesotaAges 18 years+ - NCT05526144RecruitingPhase 2
Thyroid hormone treatment for fatty liver in Veterans
This trial tests whether thyroid hormone can improve nonalcoholic steatohepatitis (fatty liver with inflammation) in Veterans. You may be asked to have a medically needed liver biopsy, and the study also focuses on safety in people with related conditions like diabetes and heart risks.
Columbia, MissouriAges 18–75 - NCT05519475RecruitingPhase 2
Gene-silencing medicine trial for adults with MASH and liver scarring
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
Chandler, ArizonaAges 18–75 - NCT03572465Recruiting
Ultrasound tests to diagnose fatty liver inflammation
This study checks whether special ultrasound measurements can help diagnose nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. You may need a liver biopsy as part of routine care, and you may also be scanned with MRI to support the study tests.
Montreal, QuebecAges 18 years+ - NCT07877272Recruiting
Better liver testing for high-risk fatty liver disease
This study tests a more detailed way to examine the liver in people with fatty liver disease who also have other health risks. The doctors want to see if this extra testing helps decide whether you need treatment.
MünsterAges 18 years+ - NCT07848191RecruitingPhase 4
Liver drug combination study for MASH and liver scarring
This study tests whether taking rezdiffra (a liver medication) together with other common diabetes or liver drugs is safe and effective for adults with MASH (fatty liver disease) and moderate-to-severe liver scarring. It may help improve liver health and reduce disease progression.
Chandler, ArizonaAges 18 years+ - NCT07830758RecruitingPhase 1
Resmetirom for fatty liver disease with heart failure
This trial tests a drug called resmetirom for people who have both a type of fatty liver disease (MASH) and a type of heart failure (HFpEF). It aims to see if the drug can help both conditions. You may be able to join if you have both conditions and meet certain health criteria.
Peoria, ArizonaAges 18 years+ - NCT04371042Recruiting
Study of liver disease and genes in people with fatty liver
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
Roma, Rome/lazio/italyAges 18 years+ - NCT04190849Recruiting
Children’s liver fat disease registry in Europe
This is a registry study collecting information about children and teens with fatty liver disease that isn’t caused by alcohol. It aims to better understand this condition and may help future research and treatments.
MaastrichtAges Up to 18 years - NCT04442334Recruiting
European registry for people with fatty liver
This registry collects health and lifestyle information from adults with suspected or confirmed fatty liver (NAFLD) to help researchers better understand the condition. You may be asked about diet, exercise, alcohol intake, and some liver-related tests.
AntwerpAges 18–100 - NCT06308757Recruiting
Studying a very low calorie keto diet for fatty liver disease with scarring
This trial tests whether a very low calorie ketogenic diet (a strict low-carb, high-fat diet) can help people with non-alcoholic steatohepatitis (NASH) who have liver scarring. Participants will follow this diet for a year and have two liver biopsies to see if their liver health improves.
BolognaAges 18 years+ - NCT07803809RecruitingPhase 1
MWN105 injection for overweight and obesity
This study tests an investigational injection called MWN105 in people who are overweight or obese but do not have diabetes. The goal is to see if it is safe and helps with weight loss.
Kunming, YunnanAges 18–50 - NCT07795164RecruitingPhase 3
Study of pemvidutide for liver scarring from MASH
This study tests an investigational medicine called pemvidutide to see if it can reduce liver scarring in people with MASH (a liver condition linked to excess weight and metabolic issues). It may help improve liver health and potentially slow or reverse the condition.
North Little Rock, ArkansasAges 18–75 - NCT07763015RecruitingPhase 2
Resmetirom for children with metabolic liver disease
This study tests a daily pill, resmetirom, to see if it can reduce fat and scarring in the livers of children and teens with MASH, a type of fatty liver disease. It may help improve liver health and prevent further damage.
Indianapolis, IndianaAges 6–17 - NCT07737340Recruiting
Metabolic liver disease in new HIV patients
This study looks at liver health in people newly diagnosed with HIV, before they start HIV treatment. It aims to understand early changes in the liver related to metabolism.
Ankara, AnkaraAges 18 years+ - NCT07718126RecruitingPhase 4
Pre-surgery rehab for obese liver donors with MASLD using Mazdutide
This trial tests if a medicine called Mazdutide can help overweight living liver donors who have a fatty liver condition (MASLD) lose weight and improve their liver health before donating part of their liver. It aims to make the donation safer and more successful.
Hefei, AnhuiAges 18–60 - NCT05480696RecruitingPhase 2
Soluble fiber supplement for fatty liver in kids
This Phase 2 study tests whether a soluble fiber supplement can improve fatty liver disease in children who have obesity and confirmed NAFLD. It may help reduce liver fat and related liver enzyme elevations measured during clinic visits and MRI.
Hamilton, OntarioAges 8–17 - NCT07632677Recruiting
Testing a liver inflammation score in diabetes and fatty liver
This study tests whether a new scoring method can help doctors identify liver inflammation in patients who have both type 2 diabetes and a fatty liver. The goal is to find an easier, safer way to assess liver health without invasive procedures.
Bengbu, AnhuiAges 18 years+ - NCT05165706Recruiting
Study of how obesity affects insulin resistance over time
This study follows adults over time to understand how weight and body chemistry relate to insulin resistance. It may help researchers learn why insulin resistance happens and what could prevent or improve it.
Stanford, CaliforniaAges 35–65 - NCT07541469Recruiting
Safety Registry for Rezdiffra Use During Pregnancy and Breastfeeding
This registry collects information about the safety of a liver disease medication called Rezdiffra (resmetirom) when used during pregnancy or while breastfeeding. Researchers want to understand if the medication affects the health of pregnant women, babies, and nursing infants.
West Conshohocken, PennsylvaniaAges Any age - NCT07481734RecruitingPhase 2
Tesamorelin for reducing liver fat in fatty liver disease
This trial tests if tesamorelin, a daily injection, can reduce liver fat in adults with fatty liver disease. It may help people whose liver has fat but is not yet scarred into cirrhosis.
Shenzhen, GuangdongAges 18–75 - NCT07463287Recruiting
Fatty liver and colorectal polyp risk study
This study looks at whether certain gene activity in people with fatty liver disease can predict the risk of developing colorectal polyps. It may help doctors find high-risk patients earlier.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07427680RecruitingPhase 1/Phase 2
Study of TGM-312-SC01 for MASH patients
This trial tests a new drug called TGM-312-SC01 to see if it can help people with MASH (a type of fatty liver disease that causes inflammation and damage). It is for adults aged 18 to 70 who are otherwise healthy or have MASH.
LondonAges 18–70
Hear when a new Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for steatohepatitis?
- Yes. Clin2 currently lists 95 recruiting steatohepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a steatohepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a steatohepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.